Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Advances in Therapy - United States
doi 10.1007/s12325-019-00991-w
Full Text
Open PDFAbstract
Available in full text
Date
May 28, 2019
Authors
Publisher
Springer Science and Business Media LLC